Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CAMBRIDGE, Mass., Jan. 11, 2018 -- Manus Bio Inc. (Manus Bio), a company which produces complex natural products through advanced fermentation, announced today that it has received funding from the Bill & Melinda Gates Foundation for the development of a scalable and cost-effective production method for artemisinin, a key therapeutic for treating malaria. Manus Bio will use its proprietary microbial chassis and unique enzyme engineering approaches to develop an advanced fermentation process for low-cost manufacturing of artemisinin.
"Malaria remains one of the largest health problems in the world today which, despite great progress in recent years, still kills over 600,000 people in a given year. Artemisinin combination therapies are recommended by the World Health Organization as first line treatment of malaria, but the vast majority of artemisinin produced today is derived from plants. With the support of the Bill & Melinda Gates Foundation, we are deploying our fermentation technology to lower the cost of artemisinin, create a stable supply, and expand its use," said Dr. Ajikumar Parayil, CEO of Manus Bio.
About Artemisinin
Artemisinin was the subject of the 2015 Nobel Prize in Medicine awarded to Tu Youyou based on her work in identifying the molecule as a potential treatment for malaria. Tu researched Traditional Chinese Medicine which led her to identify an extract from the plant Artemisia annua (sweet wormwood) as a treatment for malaria.
About Manus Bio
Manus Bio is a global leader in the use of advanced fermentation technology for manufacturing complex, bioactive natural products as flavors, fragrances, food ingredients, biopesticides, and pharmaceuticals. The core team and technology are from the Massachusetts Institute of Technology (MIT), and the company is headquartered in Cambridge, MA, USA. For more information, visit www.manusbio.com.
Contact: [email protected]
